Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases

α
Magbri A MD
Magbri A MD
σ
Awad Magbri
Awad Magbri
ρ
Hervas JG
Hervas JG
Ѡ
Eussera El-Magbri
Eussera El-Magbri
¥
Mariam El-Magbri
Mariam El-Magbri
§
Taha El-Magbri
Taha El-Magbri
χ
Llach F
Llach F
α Pine (Partners in Nephrology and Endocrinology)

Send Message

To: Author

Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases

Article Fingerprint

ReserarchID

294NW

Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages (1-4) as defined by K/DOQI. A total of 96 patients (48.96% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were (20, 27, 32, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table -1.Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups. A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared. PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 -169 pmol/l). The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin).

References

32 Cites in Article
  1. C Jones,G Mcquillan,J Kusek (1998). Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey.
  2. Advisory Nkf) ; K/Doqi),Board (2002). IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000.
  3. Y Fang,C Ginsberg,T Sugatani (2014). Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.
  4. R Pereira,H Juppner,Azucena Serrano,C (2009). Pttren of FGF-23, DMPI, and MEPE expression in patients with chronic kidney disease.
  5. Y Sabbagh,F Graciolli,O' Brien,S (2012). Repression of osteocyte Wnt/B-catenin signaling is as early event in the progression of renal osteodystrophy.
  6. R Oliveira,A Cancela,F Graciolli (2010). Early control of PTH and FGF-23 in nonmorphosphatemic CKD patients a new target in CKD-MBD therapy?.
  7. T Isakova,P Wahl,G Vargas (2011). Correction to "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease".
  8. O Gutierrez,T Isakova,E Rhee (2005). Fibroblast growth factor-23 mitigate hyperphosphatemia but accentuate calcitriol deficiency in chronic kidney disease.
  9. J Cunningham,F Locatelli,M Rodriguez (2011). Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
  10. A Levin,G Bakris,M Molitch (2007). Prevelance of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
  11. T Pitts,B Piraino,R Mitro (1988). Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
  12. Kevin Martin,Esther González (2007). Metabolic Bone Disease in Chronic Kidney Disease.
  13. D Kates,D Sherrard,D Andress (1997). Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.
  14. K Hruska,S Teitelbaum (1995). Renal osteodystrophy.
  15. A Fournier,P Moriniere,Ben Hamida,F (1992). Use of alkaline calcium salts as phosphate binder in uremic patients.
  16. F Liach (1995). Secondary hyperparathyroidism in renal failure; The trade-off hypothesis revisited.
  17. J Silver,R Levi (2005). Cellular and molecular mechanisms of secondary hyperparathyroidism.
  18. James Wetmore,Shiguang Liu,Ron Krebill,Rochelle Menard,L Quarles (2010). Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD.
  19. Hitoshi Saito,Akira Maeda,Shu-Ichi Ohtomo,Michinori Hirata,Kenichiro Kusano,Shigeaki Kato,Etsuro Ogata,Hiroko Segawa,Ken-Ichi Miyamoto,Naoshi Fukushima (2005). Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo.
  20. K Koenig,J Lindberg,J Zerwekh (1992). Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease.
  21. L Wilson,A Felsenfeld,M Drezner,F Liach (1985). Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D.
  22. O Gutierrez,T Isakova,D Andress (2008). Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease.
  23. C Hsu,S Patel,E Young,R Vanholder (1994). The biological action of calcitriol in renal failure.
  24. J Silver,T Naveh-Many,H Mayer (1986). Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.
  25. H Malluche,H Mawad,N Koszewski (2002). Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure.
  26. P Brumbaugh,M Hughes,M Haussler (1975). Cytoplasmic and nuclear binding components for 1alpha 25-dihydroxyvitamin D3 in chick parathyroid glands.
  27. M Denda,J Finch,A Brown (1996). 1,25dihydroxyvitamin D3 and 22-oxacacitriol revent the decrease in vitamin D receptor content in parathyroid glands of uremic rats.
  28. E Slatopolsky,C Weerts,J Thielan (1984). Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients.
  29. N Fukuda,H Tanaka,Y Tominaga (1993). Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.
  30. Mariano Rodriguez,Edward Nemeth,David Martin (2005). The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
  31. Yan Li,Michael Amling,Alison Pirro,Matthias Priemel,Jennifer Meuse,Roland Baron,Gunter Delling,Marie Demay (1998). Normalization of Mineral Ion Homeostasis by Dietary Means Prevents Hyperparathyroidism, Rickets, and Osteomalacia, But Not Alopecia in Vitamin D Receptor-Ablated Mice<sup>1</sup>.
  32. Dibyendu Panda,Dengshun Miao,Isabel Bolivar,Jiarong Li,Rujuan Huo,Geoffrey Hendy,David Goltzman (2004). Inactivation of the 25-Hydroxyvitamin D 1α-Hydroxylase and Vitamin D Receptor Demonstrates Independent and Interdependent Effects of Calcium and Vitamin D on Skeletal and Mineral Homeostasis.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Magbri A MD. 2016. \u201cHormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 16 (GJMR Volume 16 Issue F2): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-F Classification: NLMC Code: WJ 378, WJ 300
Version of record

v1.2

Issue date

April 30, 2016

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 3853
Total Downloads: 1839
2026 Trends
Related Research

Published Article

This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages (1-4) as defined by K/DOQI. A total of 96 patients (48.96% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were (20, 27, 32, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table -1.Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups. A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared. PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 -169 pmol/l). The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin).

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases

Awad Magbri
Awad Magbri
Hervas JG
Hervas JG
Eussera El-Magbri
Eussera El-Magbri
Mariam El-Magbri
Mariam El-Magbri
Taha El-Magbri
Taha El-Magbri
Llach F
Llach F

Research Journals